Shanghai Universal Biotech Co

Shanghai Universal Biotech Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Universal Biotech Co (301166.SZ) as of Oct 26, 2026 is -41.95 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -10.06 M CNY — a change of 317.12% (lower).

EBITDA

-41.95 MCNY

YoY

317.12%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Universal Biotech Co is 2025 -41.95 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Universal Biotech Co was 2024 -10.06 M CNY. It decreases by 317.12% lower compared to the previous year.

The Shanghai Universal Biotech Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
53.99 M CNY
Jan 1, 2019
84.00 M CNY
Jan 1, 2020
100.06 M CNY
Jan 1, 2021
144.64 M CNY
Jan 1, 2022
110.84 M CNY
Jan 1, 2023
26.58 M CNY
Jan 1, 2024
-10.06 M CNY
Jan 1, 2025
-41.95 M CNY
The Shanghai Universal Biotech Co EBITDA history
YEAREBITDAYoY
-41.95 MCNY+317.12%
-10.06 MCNY-137.83%
26.58 MCNY-76.01%
110.84 MCNY-23.37%
144.64 MCNY+44.55%
100.06 MCNY+19.11%
84.00 MCNY+55.58%
53.99 MCNY+396.24%
10.88 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Universal Biotech Co Stock analysis

What does Shanghai Universal Biotech Co do? Shanghai Universal Biotech Co., Ltd. generates revenue through the provision of life science research services, including the supply of third-party brand life science instruments and consumables, alongside its own independent brand products. The company's life science reagents, such as immunological reagents based on antibodies and antibody-related reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, are primarily sourced from third-party brands with supplementary independent brand offerings. Clients purchasing these products include research institutions and laboratories requiring comprehensive technical services like experimental services and technical support. The company focuses on life science instruments and consumables, covering detection, analysis, and sample preparation, while its comprehensive technical services support the operational needs of its clients. The business model emphasizes third-party brand products as the main supply, with independent brand products serving as a supplement. This approach allows Shanghai Universal Biotech to offer a diverse range of life science reagents and instruments without the need for extensive in-house manufacturing. The company's client base primarily consists of entities within the life science research sector seeking reliable reagents, instruments, and technical support to advance their scientific work. By leveraging third-party brands for core products and developing its own independent brand for supplementary offerings, the company optimizes its product portfolio to meet market demands effectively. Shanghai Universal Biotech's revenue streams are derived from the sale of life science reagents, instruments, and consumables, alongside comprehensive technical services. The life science reagents category includes immunological reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, all of which are supplied through a mix of third-party and independent brands. Instruments and consumables focus on detection, analysis, and sample preparation, catering to the technical needs of research institutions. The comprehensive technical services, such as experimental services and technical support, further enhance the value proposition for clients requiring end-to-end solutions in life science research. Shanghai Universal Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Universal Biotech Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Universal Biotech Co is -41.95 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shanghai Universal Biotech Co changed from -10.06 M CNY to -41.95 M CNY, representing a 317.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Shanghai Universal Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Shanghai Universal Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Shanghai Universal Biotech Co

All Key Metrics — Shanghai Universal Biotech Co